VPTDF - Ventripoint Provides Corporate Update on Development of Artificial Intelligence Engine to Automate Heart Analysis
(via TheNewswire)
Toronto, Ontario / TheNewswire / August 13, 2018 - Ventripoint Diagnostics Ltd. ("Ventripoint" or the "Company", TSXV:VPT) is pleased to present an update on its progress to provide better tools for cardiac analysis to cardiologists to improve diagnosis and treatment of heart disease.
Software upgrades to speed analysis and improve reproducibility between exams
The Company previously announced (see NR, March 19, 2018) a collaboration with Ryerson University to use its Artificial Intelligence (AI) expertise to develop a software engine to automatically detect all four chambers of the heart in echocardiographic views. If successful, this will reduce time spent on analysis and training, and allow sequential exams conducted by different users to be compared with confidence. Even today, the comparison of sequential exams is difficult to interpret due to operator variability in image acquisition, making analysis, and therefore disease progression hard to quantify. Automated analysis will ensure comparability between sequential studies.
The University researchers have completed an initial prototype of the AI engine. This software can be used to detect the end systolic and end diastolic frames in cardiac video clips in a number of different views. In initial testing with images provided by the Company, results were impressive with an up to 90% accuracy rate in identifying cardiac ultrasound views. More images are being provided to the Ryerson team to further the development of their deep-learning algorithm to enable automatic, real-time cardiac-feature detection using AI on ultrasound imaging.
It is important to accurately assess the heart using all ultrasound imaging machines and the faster the better. The Ryerson project is aimed at offering a real-time automated analysis package for cardiac analysis. An accurate reproducible result is critical in assessing disease progression. We are encouraged with the progress of our collaboration.
Annual General Meeting
The Company is holding its Annual General Meeting today at its corporate offices in Toronto at 2:00 pm EST. The prototype of the new VMS+ 3.0 will be available for viewing. More details are included in the circular, which has been mailed to shareholders of record.
About Ventripoint Diagnostics Ltd.
Ventripoint's technology is a leading Artificial Intelligence (AI) approach known as Knowledge-Based Reconstruction (KBR), used to create applications to monitor heart disease, a leading cause of death worldwide. The VMS+ is the first cost-effective and accurate AI tool for measuring whole heart function using conventional ultrasound. The Company has developed a suite of applications for all major heart diseases and is actively commercializing the approach to improve cardiac care.
For further information please contact:
Dr. George Adams, CEO, Telephone: (519) 803-6937
Email: gadams@ventripoint.com
Forward Looking Statements:
This news release contains forward-looking statements and forward-looking information within the meaning of applicable securities laws. The use of any of the words "expect", "anticipate", "continue", "estimate", "objective", "ongoing", "may", "will", "project", "should", "believe", "plans", "intends" and similar expressions are intended to identify forward-looking information or statements. The forward-looking statements and information are based on certain key expectations and assumptions made by the Corporation. Although the Corporation believes that the expectations and assumptions on which such forward-looking statements and information are based are reasonable, undue reliance should not be placed on the forward-looking statements and information because the Corporation can give no assurance that they will prove to be correct. Since forward-looking statements and information address future events and conditions, by their very nature they involve inherent risks and uncertainties. Actual results could differ materially from those currently anticipated due to a number of factors and risks. Other factors, which could materially affect such forward-looking information are described in the risk factors in the Corporation's most recent annual management's discussion and analysis that is available on the Corporation's profile on SEDAR at www.sedar.com. Readers are cautioned that the foregoing list of factors is not exhaustive. The forward-looking statements included in this news release are expressly qualified by this cautionary statement. The forward-looking statements and information contained in this news release are made as of the date hereof and the Corporation undertakes no obligation to update publicly or revise any forward-looking statements or information, whether as a result of new information, future events or otherwise, unless so required by applicable securities laws.
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Copyright (c) 2018 TheNewswire - All rights reserved.